Table 2.
Treatment outcomes and adverse events of first-line mFFX.
| n = 103 | ||
|---|---|---|
| First-line treatment period (months) | ||
| Median (range) | 6.8 (0.7–30.1) | |
| Complete response, n (%) | 0 (0) | |
| Partial response, n (%) | 27 (26.2) | |
| Stable disease, n (%) | 45 (43.7) | |
| Progressive disease, n (%) | 31 (30.1) | |
| Overall response rate, % | 26.2% | |
| Disease control rate, % | 69.9% | |
| Reason for discontinuing first-line treatment, n (%) | ||
| Tumor progression | 101 (98.1) | |
| Intolerance | 2 (1.9) | |
| Peripheral neuropathy at the end of first-line mFFX, n (%) | ||
| Grade 1 | 77 (74.7) | |
| Grade 2 | 25 (24.3) | |
| Grade 3 | 1 (1.0) |
mFFX, modified FOLFIRINOX.